Search
Filter Results
Displaying 51–60 of 758 for “retinitis clinical trial”
-
Mar 11, 2026
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
Research NewsFirst-of-its-kind small molecule therapy targets protein misfolding at the root of RHO-adRP
-
Dec 2, 2022
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
Research NewsThe LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Nov 15, 2019
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
Mar 20, 2014
UCI Stem-Cell Pioneer Poised to Launch Clinical Trial for RP Patients
Research NewsDr. Henry Klassen’s progenitor-based therapy has the potential to rescue a variety of retinal cells — including rods, cones, retinal pigment epithelium and ganglion cells — and, therefore, may save vision in people with a wide range of conditions.
-
Sep 17, 2024
Research NewsThe Phase 3 trial is expected to begin in Q1 2025
-
Feb 27, 2020
Researchers Report Six-Month Results from Biogen-Sponsored XLRP Gene Therapy Clinical Trial
Research NewsVision improvements observed with medium and high doses
-
Mar 30, 2023
Research NewsMost participants with advanced retinitis pigmentosa (RP) in the trial had improved navigation and/or object discrimination in reduced lighting conditions
-
May 3, 2021
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Jul 27, 2020
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
Research NewsThe emerging therapy is designed to work independent of the mutated gene causing vision loss
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.